Regulation - North America, Ophthalmics

Filter

Current filters:

North AmericaOphthalmics

Popular Filters

Alimera says FDA advisory committee on Iluvien no longer necessary

Alimera says FDA advisory committee on Iluvien no longer necessary

19-12-2013

US ophthalmic pharma specialist Alimera Sciences has entered into labeling discussions with the US Food…

Alimera SciencesIluvienNorth AmericaOphthalmicsPharmaceuticalpSividaRegulation

Drug approvals for Bayer in USA and Japan

Drug approvals for Bayer in USA and Japan

23-11-2013

There were two pieces of good news for German Pharma and chemicals major Bayer on Friday (November 22),…

AmgenAsia-PacificBayerBiotechnologyEyleaNexavarNorth AmericaOncologyOnyx PharmaceuticalsOphthalmicsPharmaceuticalRegeneronRegulation

Positive FDA panel recommendation for Vanda’s tasimelteon

Positive FDA panel recommendation for Vanda’s tasimelteon

15-11-2013

The US Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee…

HetliozNorth AmericaOphthalmicsPharmaceuticalRegulationtasimelteonVanda Pharmaceuticals

Eylea filed for EU and US approval in diabetic macular edema

Eylea filed for EU and US approval in diabetic macular edema

07-11-2013

US biotech firm Regeneron Pharmaceuticals says its partner German drug major Bayer has submitted an application…

BayerDiabetesEuropeEyleaNorth AmericaOphthalmicsPharmaceuticalRegeneronRegulation

FDA calls for new trial before it can approve Alimera’s Iluvien

FDA calls for new trial before it can approve Alimera’s Iluvien

18-10-2013

USA-based ophthalmic biopharma specialist Alimera Sciences says that it has received a third Complete…

Alimera SciencesIluvienNorth AmericaOphthalmicsPharmaceuticalpSividaRegulation

Back to top